KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Cash from Discontinued Operations (2020 - 2022)

Historic Cash from Discontinued Operations for Pfizer (PFE) over the last 9 years, with Q3 2022 value amounting to -$5.0 million.

  • Pfizer's Cash from Discontinued Operations fell 12941.18% to -$5.0 million in Q3 2022 from the same period last year, while for Oct 2022 it was -$332.0 million, marking a year-over-year decrease of 11583.97%. This contributed to the annual value of -$343.0 million for FY2021, which is 10887.91% down from last year.
  • As of Q3 2022, Pfizer's Cash from Discontinued Operations stood at -$5.0 million, which was down 12941.18% from -$327.0 million recorded in Q4 2021.
  • In the past 5 years, Pfizer's Cash from Discontinued Operations registered a high of $2.4 billion during Q3 2020, and its lowest value of -$327.0 million during Q4 2021.
  • Over the past 3 years, Pfizer's median Cash from Discontinued Operations value was $17.0 million (recorded in 2021), while the average stood at $564.4 million.
  • In the last 5 years, Pfizer's Cash from Discontinued Operations tumbled by 9807.26% in 2021 and then plummeted by 12941.18% in 2022.
  • Over the past 3 years, Pfizer's Cash from Discontinued Operations (Quarter) stood at $2.4 billion in 2020, then tumbled by 113.55% to -$327.0 million in 2021, then surged by 98.47% to -$5.0 million in 2022.
  • Its last three reported values are -$5.0 million in Q3 2022, -$327.0 million for Q4 2021, and $17.0 million during Q3 2021.